You’re offline. This is a read only version of the page.
Toggle navigation
Research Registry
Research Registry
Browse the Research Registry
Search the Research Registry
Useful links
Useful links
Public Data Browser
Support for grant applications
PanelApp
Research Management Twitter
Research Environment User Guide
Research Environment videos
Research Environment Training Sessions
News
Help
Help
Service Desk
Research Environment User Guide
For the public
All
All
Web Pages
Search Filter
All
Web Pages
Search
Sign in
Research Portal
Home
Research Registry
Browse the Research R...
Browse the research registry public
Browse the research registry
In this section
Browse the Research Registry
Search the Research Registry
Research registry ID
*
Date submitted
*
Project lead
Title
*
Oligogenic pathomechanisms in neurodevelopmental disorders
Community 1
*
Community 2
Community 3
Lay summary
*
For a large fraction of patients with neurodevelopmental disorders (NDD) who are undergoing genome analysis, a gene variant can be identified that is clearly considered to be the reason of the disease. This implies that there is still a relevant fraction of patients for which this cannot be achieved. The health status of these patients is typically unclear for decades, and a final clarification of their disease can bring great relief to the patients themselves and to their families. It is very likely that the diagnostic failure in these cases is due to a more complex genetic cause than only one single gene variant. Instead, several gene variants inherited from both mother and father in a new combination could be the reason for the disease. While it has been scientifically very challenging to identify a specific disease-causing combination of gene variants in a patient, the Genomics England program provides for the first time a sufficiently large cohort of NDD patients to systematically search for such potential multi-gene signatures in their genomes. Our research can provide relief to some individual patients by clarifying the genetic causes of their disease. Moreover, it will showcase a fundamentally new data-driven approach for genome analysis in NDD and other rare diseases.